The treatment of systemic lupus erythematosus (SLE) presents a significant therapeutic challenge: multi-organ involvement and a variable disease course characterized by clinical exacerbations and remissions make it difficult to predict outcome. Few products have been specifically developed in this clinical indication and most accepted therapies have not been tested in randomized controlled trials in SLE. A variety of biologic agents under investigation as potential treatments for SLE are designed to interfere with specific immunologic responses, hopefully avoiding gneralized immunosuppression. These include therapies to downregulate IL-10 and/or upregulate TGFb production. Agents which interfere with T cell activation and T cell–B cell collaboration, such as CTLA4-Ig and anti-CD40 ligand monoclonal antibodies, may result in long term therapeutic benefit; alone or in combination, even following brief treatment courses. Products designed to decrease production of anti-dsDNA antibodies or inhibit complement activation may prevent immune complex deposition and amerliorate organ-specific manifestations such as renal disease. More aggressive interventions include gene therapy and stem cell transplantation. As these agents enter clinical trials, efforts to develop international consensus regarding trial methodology and outcome measures will be crucial to their successful development.
Park Y , Lee SK , Kim DS et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus . Clin Exp Rheumatol1998; 16: 283–288 .
2.
Rönnelid J , Nillson B . Immune complexes from SLE sera induce IL-10 production. A possible vicious circle maintaining B cell hyperactivity in SLE . Arthritis Rheum1998; 41: S67-S67 .
3.
Alcocer-Varela J , Llorente L , Alarcon-Segovia D . Immunoregulatory circuits and potential treatment of connective tissue diseases . Int Arch Allergy Immunol1996; 111: 348–354 .
4.
Grondal G , Kristjansdottir H , Traustadottir KH et al. IL-10 production and apoptosis in SLE patients and their spouses in icelandic SLE multicase families . Arthritis Rheum1998; 41: S283-S283 .
5.
Al-Janadi M , Al-Dalaan A , Al-Balla S et al. IL-10 secrtion in systemic lupus erythematosus and rheumatoic arthritis: IL-10 dependent CD4 / CD45RO / T cell-B cell antibody synthesis . J Clin Immunol1996; 16: 198–207 .
6.
Ishida H , Muchamuel T , Sakaguchi S et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice . J Exp Med1994; 179: 305–310 .
7.
Llorente L , Zou W , Lewy Y et al. Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus . J Exp Med1995; 181: 839–844 .
8.
Llorente L , Richaud-Patin Y , Garcia-Padilla C et al. Clinicial and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus . Arthritis Rheum2000; 43: 1790–1800 .
9.
Evans C , Ghivizzani SC , Kang R et al. Gene therapy for rheumatic diseases . Arthritis Rheum1999; 42: 1–16 .
10.
Raz E , Dudler J , Lotz M et al. Modulatoin of disease activity in murine systemic lupus erythematosus by cytokine gene delivery . Lupus1995; 4: 286–292 .
11.
Foy TM , Aruffo A , Bajorath J et al. Immune regulation by CD40 and its ligand of p39 (review) . Ann Rev Immunol1996; 14: 591–561 .
12.
Grammer AC , Bergman MC , Miura Y et al. The CD40 ligand expressed by human B cells costimulates B cell responses . J Immunol1995; 154: 4996–5010 .
13.
Grewal IS , Flavell RA . A central role of CD40 ligand in the regulation of CD4 / T cell responses . Immunol Today1996; 17: 410–414 .
14.
Kato K , Santana-Sahagun E , Rassenti LZ et al. Elevated soluble CD40-ligand (CD154) in plasma of patients with systemic lupus erythematosus . Arthritis Rheum1998; 41: S71-S71 .
15.
Vakkalanka RK , Kirou KA , Raman C et al. Kinetics of CD40 ligand mRNA expression in systemic lupus erythematosus patients and healthy control . Arthritis Rheum1998; 41: S235-S235 .
16.
Vakkalanka RK , Woo C , Kirou KA et al. Soluble CD40 ligand (sCD40L) in sera from patients with SLE is present at concentrations that can mediate B cell activation . Arthritis Rheum1998; 41: S235-S235 .
17.
Yellin MJ , D'Agati V , Parkinson G et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides . Arthritis Rhem1997; 40: 124–134 .
18.
Mohan C , Shi Y , Laman JD , Datta SK . Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis . J Immunol1995; 154: 1470–1480 .
19.
Kalled SL , Cutler AH , Datta SK , Thomas DW . Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function . J Immunol1998; 160: 2158–2165 .
20.
Davidson A , Budha L , Reddy B , Vashnaw A , Furie R . The effect of Anti CD40L on B cells in human SLE . Arthritis Rheum2000; 43: S271-S271 .
21.
Davis JC , Totoritis MC , Sklenar TA , Wofsy D . Results of a phase 1 single dose escalating trial of a humanized antiCD40L monoclonal antibody (IDEC 131) in patients with SLE . Arthritis Rheum1999; 42: S281-S281 .
22.
Kalunian K , Davis J , Merrill JT et al. Treatment of SLE by inhibition of T cell costimulation . Arthritis Rheum2000; 43: S271-S271 .
23.
Reiser H , Stadecker MJ . Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases . New Engl J Med1996; 335: 1369–1375 .
24.
Linsley PS , Ledbetter JA . The role of the CD28 receptor during T cell responses to antigen . Ann Rev Immunol1993; 11: 191–212 .
25.
Finck BK , Linsley PS , Wofsy D . Treatment of murine lupus with CTLA4Ig . Science1994; 265: 1225–1227 .
26.
Daikh ID , Palmer B , Finck B et al. CTLA4Ig inhibits cytokine production by CD4 T cells in NZB/NZW lupus-prone mice . Arthritis Rheum1996; 39: S106-S106 .
27.
Daikh DI , Wofsy D . Reversal of advanced murine lupus nephritis with combined CTLA4Ig and cyclophosphamide . Arthritis Rheum1998; 41: S140-S140 .
28.
Chan OC , Kaufman E , Daikh DI . CTLA4Ig substantially prolongs benefits of cyclophosphamide for lupus nephritis . Arthritis Rheum2000; 43: S94-S94 .
29.
Guinan EC , Boussiotis VK , Nueberg D et al. Transplantation of anergic histoincompatible bone marrow allografts . New Engl J Med1999; 340: 1704–1714 .
30.
Abrams JR , Lebwohl MG , Guzzo CA et al. CTLA4Ig mediated blockade of T-cell costimulation in patients with psoriasis vulgaris . J Clin Invest1999; 103: 1243–1252 .
31.
Daikh DI , Finck BK , Linsley PS et al. Long term inhibition of murine lupus by brief simultaneous blockade of the b7=CD28 and CD40=gp39 costimulation pathways . J Immunol1997; 159: 304–308 .
32.
Wang D , Reddy B , Mihara M et al. Mechanism of action of short term combination CTLAYIg/CD4OL therapy in mature SLE . Arthritis Rheum2000; 43: S92-S92 .
33.
Jacob L , Lety MA , Luvard D , Bach J-F . Binding of a monoclonal anti DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus patheogenesis . J Clin Invest1985; 75: 315–317 .
34.
Fillit H , Shibata S , Sasaki T et al. Autoantibodies to the protein core of vascular basement membrane heparin sulfate proteoglycan in systemic lupus erythematosus . Autoimmunity1993; 14: 243–249 .
35.
Shoenfeld Y et al. Intravenous Immunoglobulins. Lupus (in press).
36.
Strand V . The mechanisms of action for intravenous immunoglobulin therapy of autoimmune diseases and acquired immune deficiency. In: Lee ML , Strand V (eds). Intravenous Immunoglobulins in Clinical Practice. Marcel Dekker: New York , 1997, pp 23–36.
37.
Shoenfeld Y , Krause I , Blank M . New methods of treatment in a experimental murine model of systemic lupus erthematosus induced by idiotypic manipulation . Ann Rheum Dis1997; 56: 5–11 .
38.
Williams RC , Malone CC , Fry G , Silvestris F . Affinity columns containing anti-DNA Id / human myeloma proteins adsorb human epibodies from intravenous gamma globulin . Arthritis Rheum1997; 40: 683–693 .
39.
Prasad NKA , Papoff G , Zeuner A et al. Therapeutic preparations of normal polyspecified IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the fas apoptic pathway . J Immunol1998; 161: 3781–3790 .
40.
Jones DS , Barstad PA , Field MJ et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleo-tide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis . J Med Chem1995; 38: 2138–2144 .
41.
Weisman MH , Blustein HG , Berner CM et al. Reduction in circulating dsDNA antibody titer after adminstration of LJP 394 . J Rheumatol1997; 24: 314–318 .
42.
Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol (in press).
43.
Sem , DS , McNeeley , PA , Linnik MD . Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of anti-DNA antibodies . Arch Biochem Biophys1999; 372: 62–68 .
44.
Linnik MD , McNeeley PA , Iverson MG . Affinity of antibodies for LJP394 influences pharmacodynamic response to LJP 394 in SLE patients with positive dsDNA antibody titers . Arthritis Rheum2000; 43: S241-S241 .
45.
Alarcon-Segovia D , Tumlin J , Furie R et al. SLE trial shows fewer renal flares in LJP 394 treated patients with high affinity antibodies to LJP 394: 90-05 trial results . Arthritis Rheum2000; 43: S272-S272 .
46.
Linnik MD , Bagn RG . Effect of LJP 394 on patients with greatest impairment of renal function at baseline in the 90-05 trial . Arthritis Rheum2000; 43: S241-S241 .
47.
Iverson GM , Victoria EJ , Marquis D . Anti B2 glycoprotein I autoantibodies recognize an epitope on the first domain of B2GPI . Proc Natl Acad Sci USA1998; 95: 15542–15546 .
48.
Iverson GM , Jones DS , Marquis D et al. A chemically defined, toleragen based approach for targeting anti B2 glycoprotein I anti-bodies . Lupus1998; 7(Suppl): S166–S169 .
49.
Matis LA , Rollins SA . Complement-specific antibodies: designing novel anti-inflammatories . Nature Med1995; 1: 839–842 .
50.
Wang Y , Hu Q , Madre JA et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5 . Proc Natl Acad Sci USA1996; 93: 8563–8568 .
51.
Ravirajan CT , Wang Y , Matis L et al. Effect of anti-IL 10 and anti-C5 on human anti-ds DNA antibody induced kidney damage . Arthritis Rheum1998; 41: S177-S177 .
52.
Wang Y , Hu O , Kristan J et al. Subcutaneous administratoin of anti-C5 monoclonal antibody induces systemic complement inhibition and ameliorates immune complex mediated inflammatory responses . Arthritis Rheum1996; 39: S245-S245 .
53.
Matis L . Presentation, Innovative therapies in autoimmune diseases , sponsored by the American College of RheumatologyApril 4, 1997, Washington, DC.
54.
Raz E , Dudler J , Lotz, M et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery . Lupus1995; 4: 286–292 .
55.
Evans C , Whalen JD , Ghivizzani SC et al. Gene therapy in autoimmune diseases . Annal Rheum Dis1998; 57: 125–127 .
56.
Chuzhin Y , Reddy B , Budhai L et al. Prolonged survival in murine SLE by adenoviral mediated CTLA4Ig gene transfer . Arthritis Rheum1998; 41: S140-S140 .
57.
Zhang H , Yang Y , Horton JL et al. Amelioration of collagen induced arthritis by CD95 (Apo-1/Fas)-ligand expressing APCs as a therapy of autoimmune disease . J Clin Invest1997; 100: 1951–1957 .
58.
Tyndall A . Immunoblation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus . Lupus2001; 10: 214–215 .
